Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00160238
Status:
COMPLETED
Last Update Posted:
2006-12-22
First Post:
2005-09-09
Brief Title:
Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Menieres Disease and Having Undergone Vestibular Neurotomy
Sponsor:
Solvay Pharmaceuticals
Organization:
Solvay Pharmaceuticals
Study Overview
Official Title:
A Double-Blind Placebo-Controlled Randomized Clinical Study of the Effects of Betaserc 24 mg 1 Tablet bid Over 3 Months on Vestibular Compensation Following Vestibular Neurotomy in Patients With Disabling Menières Disease
Status:
COMPLETED
Status Verified Date:
2006-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to compare the effects of Betaserc 24mg and placebo on compensation of postural and locomotor deficits static and dynamic posturography after vestibular neurotomy in patients suffering from disabling Menières disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None